Trials / Completed
CompletedNCT04577794
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Ulcerative Colitis (UC) in participants with moderately to severely active UC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG3970 | GLPG3970 powder and solvent for oral solution reconstituted prior to use. |
| DRUG | Placebo | Placebo powder and solvent for oral solution reconstituted prior to use. |
Timeline
- Start date
- 2020-10-05
- Primary completion
- 2021-05-17
- Completion
- 2021-05-31
- First posted
- 2020-10-08
- Last updated
- 2023-01-27
- Results posted
- 2023-01-27
Locations
15 sites across 4 countries: Georgia, Moldova, Poland, Ukraine
Source: ClinicalTrials.gov record NCT04577794. Inclusion in this directory is not an endorsement.